A scoping review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations?


Journal

European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391

Informations de publication

Date de publication:
31 Mar 2023
Historique:
received: 13 07 2022
accepted: 13 10 2022
entrez: 11 1 2023
pubmed: 12 1 2023
medline: 14 1 2023
Statut: epublish

Résumé

Since 2015, the World Health Organization (WHO) has recommended prioritising testing and treatment of tuberculosis (TB) infection (TBI) in 11 high-risk groups. With new options emerging for TB preventive treatment, we conducted a scoping review, in consultation with the WHO's Global Tuberculosis Programme, to explore the evidence for other population groups at potentially high risk of progression to active TB. We searched six databases for preprints and articles published between 2000 and August 2022. 18 out of 33 668 screened records were included (six meta-analyses and 12 original research studies). Most were observational studies reporting the incidence of active TB in a risk group

Identifiants

pubmed: 36631131
pii: 32/167/220127
doi: 10.1183/16000617.0127-2022
pmc: PMC9879343
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflicts of interest: All authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Am J Epidemiol. 1974 Feb;99(2):131-8
pubmed: 4810628
Int J Infect Dis. 2022 Apr;117:222-229
pubmed: 35121126
J Thorac Dis. 2020 Sep;12(9):4950-4959
pubmed: 33145069
J Am Acad Dermatol. 2020 May;82(5):1243-1245
pubmed: 31866266
Respirology. 2018 Nov;23(11):1063-1073
pubmed: 29943489
Eur Respir J. 2017 Aug 24;50(2):
pubmed: 28838977
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Clin Infect Dis. 2006 Sep 15;43(6):717-22
pubmed: 16912945
Eur Respir J. 2015 Dec;46(6):1563-76
pubmed: 26405286
Int J Tuberc Lung Dis. 2015 Aug;19(8):936-42
pubmed: 26162360
Arthritis Rheum. 2009 Mar 15;61(3):300-4
pubmed: 19248128
Int J Chron Obstruct Pulmon Dis. 2019 Sep 26;14:2219-2227
pubmed: 31576118
PLoS One. 2021 Dec 10;16(12):e0261246
pubmed: 34890419
J Am Acad Dermatol. 2013 Jul;69(1):25-33
pubmed: 23375515
Clin Infect Dis. 2023 Jan 13;76(2):245-251
pubmed: 36134743
J Antimicrob Chemother. 2019 Jan 1;74(1):218-227
pubmed: 30295760
BMC Pulm Med. 2017 May 4;17(1):82
pubmed: 28472944
Int J Tuberc Lung Dis. 2020 Sep 1;24(9):916-921
pubmed: 33156758
PLoS One. 2017 Nov 21;12(11):e0187967
pubmed: 29161276
Chest. 2014 Jun;145(6):1286-1297
pubmed: 24504044
Int J Tuberc Lung Dis. 2022 Mar 1;26(3):190-205
pubmed: 35197159
J Rheumatol. 2003 Jul;30(7):1436-9
pubmed: 12858438

Auteurs

Jacob Bigio (J)

Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
McGill International TB Centre, Montreal, QC, Canada.

Angelo Viscardi (A)

Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Genevieve Gore (G)

Department of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-infection and TB Elimination, University of Brescia, Brescia, Italy.

Alberto Matteelli (A)

Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
These authors contributed equally.

Giorgia Sulis (G)

McGill International TB Centre, Montreal, QC, Canada giorgia.sulis@mail.mcgill.ca.
Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
These authors contributed equally.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH